User profiles for M. Feldmann

Marc Feldmann

- Verified email at kennedy.ox.ac.uk - Cited by 96297

PD Dr. Maria Ilyas-Feldmann, Ph.D

- Verified email at ion.ucl.ac.uk - Cited by 4562

Role of cytokines in rheumatoid arthritis

M Feldmann, FM Brennan… - Annual review of …, 1996 - annualreviews.org
▪ Abstract Analysis of cytokine mRNA and protein in rheumatoid arthritis tissue revealed that
many proinflammatory cytokines such as TNFα, IL-1, IL-6, GM-CSF, and chemokines such …

Anti-TNFα therapy of rheumatoid arthritis: what have we learned?

M Feldmann, RN Maini - Annual review of immunology, 2001 - annualreviews.org
Rheumatoid arthritis (RA), a systemic disease, is characterized by a chronic inflammatory
reaction in the synovium of joints and is associated with degeneration of cartilage and erosion …

Development of anti-TNF therapy for rheumatoid arthritis

M Feldmann - Nature Reviews Immunology, 2002 - nature.com
The aetiology of systemic, autoimmune, chronic inflammatory diseases — such as rheumatoid
arthritis — is not known, and their pathogenesis is complex and multifactorial. However, …

[HTML][HTML] An inflammatory cytokine signature predicts COVID-19 severity and survival

…, C Cordon-Cardo, M Feldmann, S Parekh, M Merad… - Nature medicine, 2020 - nature.com
Several studies have revealed that the hyper-inflammatory response induced by severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a major cause of disease severity …

[HTML][HTML] Infliximab and methotrexate in the treatment of rheumatoid arthritis

…, M Weisman, P Emery, M Feldmann… - … England Journal of …, 2000 - Mass Medical Soc
Background Neutralization of tumor necrosis factor α (TNF-α) for three to six months reduces
the symptoms and signs of rheumatoid arthritis. However, the capacity of this approach to …

Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a …

…, J Smolen, P Emery, G Harriman, M Feldmann… - The Lancet, 1999 - thelancet.com
Background Not all patients with rheumatoid arthritis can tolerate or respond to methotrexate,
a standard treatment for this disease. There is evidence that antitumour necrosis factor α (…

Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor α (cA2) versus placebo in rheumatoid arthritis

MJ Elliott, RN Maini, M Feldmann, JR Kalden, C Antoni… - The Lancet, 1994 - Elsevier
… Prof M Feldmann is a consultant for Centocor and received research support as well as …
8 Elliott MJ, Maini RN, Feldmann M, et al. Treatment of rheumatoid arthritis with chimaeric …

Therapeutic efficacy of multiple intravenous infusions of anti‐tumor necrosis factor α monoclonal antibody combined with low‐dose weekly methotrexate in rheumatoid …

…, JN Woody, TF Schaible, M Feldmann - … : Official Journal of …, 1998 - Wiley Online Library
Objective To evaluate the efficacy, pharmacokinetics, immunogenicity, and safety of multiple
infusions of a chimeric monoclonal anti‐tumor necrosis factor α antibody (cA2) (infliximab; …

Epidemiology of benign paroxysmal positional vertigo: a population based study

…, A Radtke, F Lezius, M Feldmann… - Journal of Neurology …, 2007 - jnnp.bmj.com
Objectives: To examine the prevalence and incidence, clinical presentation, societal impact
and comorbid conditions of benign paroxysmal positional vertigo (BPPV) in the general …

Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor α

MJ Elliott, RN Maini, M Feldmann… - Arthritis & …, 1993 - Wiley Online Library
Objective. To evaluate the safety and efficacy of a chimeric monoclonal antibody to tumor
necrosis factor α (TNFα) in the treatment of patients with rheumatoid arthritis (RA). Methods. …